Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aquestive Therapeutics Releases Topline PK Data From Self-Administration Study Of Anaphylm; Meets Primary Endpoints With Comparable PK Whether Administered By Subjects Or HCPs; Final OAS Challenge Study Enrolling; Pre-NDA Meeting Anticipated By End Of Q3 2024

Author: Benzinga Newsdesk | July 25, 2024 08:05am
  • Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs)
  • Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling
  • Continues to anticipate requesting a pre-New Drug Application (NDA) meeting before the end of the third quarter

Posted In: AQST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist